Wednesday, 12 September 2012

Primovist 0.25 mmol / ml, solution for injection, prefilled syringe





1. Name Of The Medicinal Product




2. Qualitative And Quantitative Composition



Each ml contains 0.25 mmol gadoxetate disodium (Gd-EOB-DTPA disodium),equivalent to 181.43 mg gadoxetate disodium.



1 prefilled syringe with 5.0 ml contains 907 mg gadoxetate disodium,



1 prefilled syringe with 7.5 ml contains 1361 mg gadoxetate disodium,



1 prefilled syringe with 10.0 ml contains 1814 mg gadoxetate disodium.



Contains 11.7 mg sodium/ ml.



For a full list of excipients, see section 6.1.



3. Pharmaceutical Form



Solution for injection, prefilled syringe:



Clear, colourless to pale yellow liquid free from visible particles.



4. Clinical Particulars



4.1 Therapeutic Indications



Primovist is indicated for the detection of focal liver lesions and provides information on the character of lesions in T1-weighted magnetic resonance imaging (MRI).



This medicinal product is for diagnostic use by intravenous administration only.



4.2 Posology And Method Of Administration



Method of administration



Primovist is a ready-to-use aqueous solution to be administered undiluted as an intravenous bolus injection at a flow rate of about 2 ml/sec. After the injection of the contrast medium the intravenous cannula / line should be flushed using sterile 9 mg/ml (0.9 %) saline solution.



For detailed imaging information refer to section 5.1.



For additional instructions see section 6.6.



Posology



The recommended dose of Primovist is:



Adults:



0.1 ml per kg body weight Primovist.



Repeated use:



No clinical information is available about repeated use of Primovist.



Additional information on special populations



• Impaired renal function



Use of Primovist should be avoided in patients with severe renal impairment (GFR < 30 ml/min/1.73m2) and in patients in the perioperative liver transplantation period unless the diagnostic information is essential and not available with non-contrast enhanced MRI (see section 4.4). If use of Primovist cannot be avoided, the dose should not exceed 0.025 mmol/kg body weight. More than one dose should not be used during a scan. Because of the lack of information on repeated administration, Primovist injections should not be repeated unless the interval between injections is at least 7 days.



• Patients with hepatic impairment:



No dosage adjustment is necessary.



• Paediatric population



The safety and efficacy of Primovist has not been established in patients under 18 years old. Therefore, use of Primovist in this patient group cannot be recommended.



• Elderly population (aged 65 years and above)



No dosage adjustment is considered necessary. Caution should be exercised in elderly patients (see section 4.4).



4.3 Contraindications



Hypersensitivity to the active substance or to any of the excipients.



4.4 Special Warnings And Precautions For Use



The usual safety precautions for MRI must be observed, e.g. exclusion of cardiac pacemakers and ferromagnetic implants.



Diagnostic procedures that involve the use of contrast agents should be carried out under the direction of a physician with the prerequisite training and a thorough knowledge of the procedure to be performed.



After the injection, the patient should be kept under observation for at least 30 minutes, since experience with contrast media shows that the majority of undesirable effects occur within this time.



• Impaired renal function



Prior to administration of Primovist, it is recommended that all patients are screened for renal dysfunction by obtaining laboratory tests.



There have been reports of nephrogenic systemic fibrosis (NSF) associated with use of some gadolinium-containing contrast agents in patients with acute or chronic severe renal impairment (GFR< 30ml/min/1.73 m2). Patients undergoing liver transplantation are at particular risk since the incidence of acute renal failure is high in this group. As there is a possibility that NSF may occur with Primovist, it should therefore be avoided in patients with severe renal impairment and in patients in the perioperative liver transplantation period unless the diagnostic information is essential and not available with non-contrast enhanced MRI.



Haemodialysis shortly after Primovist administration may be useful at removing Primovist from the body.



There is no evidence to support the initiation of haemodialysis for prevention or treatment of NSF in patients not already undergoing haemodialysis.



• Elderly



As the renal clearance of gadoxetate may be impaired in the elderly, it is particularly important to screen patients aged 65 years and older for renal dysfunction.



• Patients with cardiovascular disease



Caution should be exercised when Primovist is administered to patients with severe cardiovascular problems because only limited data are available so far.



Primovist should not be used in patients with uncorrected hypokalemia.



Primovist should be used with special care in patients



- with known congenital long QT syndrome or a family history of congenital long QT syndrome



- with known previous arrhythmias when on drugs that prolong cardiac repolarisation



- who are currently taking a drug that is known to prolong cardiac repolarisation e.g. a class III antiarrhythmic, (e.g. amiodarone, sotalol).



Primovist may cause transient QT-prolongation in individual patients. (see section 5.3).



• Hypersensitivity



Allergy-like reactions, including shock, are known to be rare events after administration of gadolinium-based MRI contrast media. Most of these reactions occur within half an hour after administration of contrast media. However, as with other contrast media of this class, delayed reactions may occur after hours to days in rare cases. Medication for the treatment of hypersensitivity reactions as well as preparedness for institution of emergency measures are necessary.



The risk of hypersensitivity reactions is higher in case of:



- previous reaction to contrast media



- history of bronchial asthma



- history of allergic disorders.



In patients with an allergic disposition (especially with a history of the above mentioned conditions) the decision to use Primovist must be made after particularly careful evaluation of the risk-benefit ratio.



Hypersensitivity reactions can be more intense in patients on beta-blockers, particularly in the presence of bronchial asthma. It should be considered that patients on beta-blockers may be refractory to standard treatment of hypersensitivity reactions with beta-agonists.



If hypersensitivity reactions occur, injection of the contrast medium must be discontinued immediately.



• Local intolerance



Intramuscular administration may cause local intolerance reactions including focal necrosis and must therefore be strictly avoided (see section5.3).



• Excipients



This medicinal product contains 11.7 mg sodium per ml, and the dosage is 0.1 ml/kg body weight. To be taken into consideration by patients on a controlled sodium diet.



4.5 Interaction With Other Medicinal Products And Other Forms Of Interaction



As transport of gadoxetate to the liver may be mediated by OATP transporters it cannot be excluded that potent OATP inhibitors could cause drug interactions reducing the hepatic contrast effect. However, no clinical data have been presented to support that theory.



An interaction study in healthy subjects demonstrated that the co-administration of erythromycin did not influence efficacy and pharmacokinetics of Primovist. No further clinical interaction studies with other medicinal products have been performed.



• Interference from elevated bilirubin or ferritin levels in patients



Elevated levels of bilirubin or ferritin can reduce the hepatic contrast effect of Primovist (see section 5.1).



• Interference with diagnostic tests



Serum iron determination using complexometric methods (e.g. Ferrocine complexation method) may result in false values for up to 24 hours after the examination with Primovist because of the free complexing agent contained in the contrast medium solution.



4.6 Pregnancy And Lactation



• Pregnancy



There are no data from the use of gadoxetate in pregnant women. Animal studies have shown reproductive toxicity at repeated high doses (see section 5.3). Primovist should not be used during pregnancy unless the clinical condition of the woman requires use of gadoxetate.



• Lactation



Gadolinium containing contrast agents are excreted into breast milk in very small amounts (see section 5.3). At clinical doses, no effects on the infant are anticipated due to the small amount excreted in milk and poor absorption from the gut. Continuing or discontinuing breast feeding for a period of 24 hours after administration of Primovist, should be at the discretion of the doctor and lactating mother.



4.7 Effects On Ability To Drive And Use Machines



Not relevant.



4.8 Undesirable Effects



• Summary of the safety profile



The overall safety profile of Primovist is based on data from more than 1,900 patients in clinical trials, and from post-marketing surveillance.



The most frequently observed adverse drug reactions (



The most serious adverse drug reaction in patients receiving Primovist is anaphylactoid shock.



Delayed allergoid reactions (hours later up to several days) have been rarely observed.



Most of the undesirable effects were transient and of mild to moderate intensity.



• Tabulated list of adverse reactions



The adverse drug reactions observed with Primovist are represented in the table below. They are classified according to System Organ Class (MedDRA version 12.1). The most appropriate MedDRA term is used to describe a certain reaction and its synonyms and related conditions.



Adverse drug reactions from clinical trials are classified according to their frequencies. Frequency groupings are defined according to the following convention: common:



Within each frequency grouping, undesirable effects are presented in order of decreasing seriousness.



Table 1: Adverse drug reactions reported in clinical trials or during post-marketing surveillance in patients treated with Primovist






















































System Organ Class (MedDRA)




Common




Uncommon




Rare




Not known




Immune system disorders



 

 

 


Hypersensitivity / anaphylactoid reaction (e.g. shock*, hypotension, pharyngolaryngeal edema, urticaria, face edema, rhinitis, conjunctivitis, abdominal pain, hypoesthesia, sneezing, cough, pallor)




Nervous system disorders




Headache




Vertigo



Dizziness



Dysgeusia



Paresthesia



Parosmia




Tremor



Akathisia




Restlessness




Cardiac disorders



 

 


Bundle branch block



Palpitation




Tachycardia




Vascular disorders



 


Blood pressure increased



Flushing



 

 


Respiratory, thoracic and mediastinal disorders



 


Respiratory disorders



(Dyspnea*, Respiratory distress)



 

 


Gastrointestinal disorders




Nausea




Vomiting



Dry mouth




Oral discomfort



Salivary hypersecretion



 


Skin and subcutaneous tissue disorders



 


Rash



Pruritus**




Maculopapular rash



Hyperhidrosis



 


Musculoskeletal and connective tissue disorders



 


Back pain



 

 


General disorders and administration site conditions



 


Chest pain



Injection site reactions



(various kinds)***



Feeling hot



Chills



Fatigue



Feeling abnormal




Discomfort



Malaise



 


* Life-threatening and/or fatal cases have been reported. These reports originated from post-marketing experience.



**Pruritus (generalized pruritus, eye pruritus)



***Injection site reactions (various kinds) comprise the following terms: Injection site extravasation, injection site burning, injection site coldness, injection site irritation, injection site pain



• Description of selected adverse reactions



Laboratory changes such as elevated serum iron, elevated bilirubin, increases in liver transaminases, decrease of hemoglobin, elevation of amylase, leucocyturia, hyperglycemia, elevated urine albumin, hyponatremia, elevated inorganic phosphate, decrease of serum protein, leucocytosis, hypokalemia, elevated LDH were reported in clinical trials. ECGs were regularly monitored during clinical studies and transient QT prolongation was observed in some patients without any associated adverse clinical events.



Cases of nephrogenic systemic fibrosis (NSF) have been reported with other gadolinium-containing contrast agents (see section 4.4).



4.9 Overdose



No cases of overdose have been reported and no symptoms could be characterised.



Single doses of Primovist as high as 0.4 ml/kg (0.1mmol/kg) body weight were tolerated well.



In a limited number of patients, a dose of 2.0 ml/kg (0.5 mmol/kg) body weight was tested in clinical trials, more frequent occurrences of adverse events but no new undesirable effects were found in these patients.



In the event of excessive inadvertent overdose, the patient should be carefully observed including cardiac monitoring. In this case induction of QT prolongations is possible (see section 5.3).



Primovist can be removed by hemodialysis. However, there is no evidence that haemodialysis is suitable for prevention of nephrogenic systemic fibrosis (NSF).



5. Pharmacological Properties



5.1 Pharmacodynamic Properties



Pharmacotherapeutic group: paramagnetic contrast media, ATC code: V08 C A10



• Mechanism of action



Primovist is a paramagnetic contrast agent for magnetic resonance imaging.



The contrast-enhancing effect is mediated by gadoxetate (Gd EOB DTPA), an ionic complex consisting of gadolinium (III) and the ligand ethoxybenzyl-diethylenetriamine-pentaacetic acid (EOB-DTPA)



When T1-weighted scanning sequences are used in proton magnetic resonance imaging, the gadolinium ion-induced shortening of the spin-lattice relaxation time of excited atomic nuclei leads to an increase of the signal intensity and, hence, to an increase of the image contrast of certain tissues.



• Pharmacodynamic effects



Gadoxetate disodium leads to a distinct shortening of the relaxation times even at low concentrations. At pH 7, a magnetic field strength of 0.47 T and 40°C the relaxivity (r1) - determined from the influence on the spin-lattice relaxation time (T1) of protons in plasma - is about 8.18 l/mmol/sec and the relaxivity (r2) - determined from the influence on the spin-spin relaxation time (T2)- is about 8.56 l/mmol/sec. At 1.5 T and 37°C the respective relaxivities in plasma are r1 = 6.9 l/mmol/sec and r2 = 8.7 l/mmol/sec. The relaxivity displays a slight inverse dependency on the strength of the magnetic field.



EOB-DTPA forms a stable complex with the paramagnetic gadolinium ion with extremely high thermodynamic stability (log KGdl = –23.46). Gd-EOB-DTPA is a highly water-soluble, hydrophilic compound with a partition coefficient between n-butanol and buffer at pH 7.6 of about 0.011.



Due to its lipophilic ethoxybenzyl moiety gadoxetate disodium exhibits a biphasic mode of action: first, distribution in the extracellular space after bolus injection and subsequently selective uptake by hepatocytes. The relaxivity r1 in liver tissue is 16.6 l/mmol/sec (at 0.47T) resulting in increased signal intensity of liver tissue. Subsequently gadoxetate disodium is excreted into the bile.



Lesions with no or minimal hepatocyte function (cysts, metastases, the majority of hepatocellular carcinoma) will not accumulate Primovist. Well-differentiated hepatocellular carcinoma may contain functioning hepatocytes and can show some enhancement in the hepatocyte imaging phase. Additional clinical information is therefore needed to support a correct diagnosis.



The substance does not display any significant inhibitory interaction with enzymes at clinically relevant concentrations.



• Imaging



After bolus injection of Primovist, dynamic imaging during arterial, portovenous and equilibrium phases utilizes the different temporal enhancement pattern of different liver lesions as basis for the radiological lesion characterization.



The enhancement of liver parenchyma during the hepatocyte phase assists in the identification of the number, segmental distribution, visualization, and delineation of liver lesions, thus improving lesion detection. The differential enhancement/washout pattern of liver lesions contributes to the information from the dynamic phase.



The delayed (hepatocyte) phase can be investigated at 20 minutes post injection with an imaging window lasting at least 120 minutes. The diagnostic and technical efficacy results of the clinical studies show a minimal improvement at 20 minutes post injection over those at 10 minutes post injection.



The imaging window is reduced to 60 minutes in patients requiring hemodialysis and in patients with elevated bilirubin values (> 3 mg/dl).



Hepatic excretion of Primovist results in enhancement of biliary structures.



The physico-chemical characteristics of the ready-to-use solution of Primovist are as follows:












Osmolality at 37 °C (mOsm/kg H2O)




688




Viscosity at 37 °C (mPa·s)




1.19




Density at 37 °C (g/ ml)




1.0881




pH




7.4



5.2 Pharmacokinetic Properties



• Distribution



After intravenous administration the concentration time profile of Gd-EOB-DTPA was characterised by a bi-exponential decline.



Gd-EOB-DTPA distributes in the extracellular space (distribution volume at steady state about 0.21 l/kg).



The substance elicits only minor protein binding (less than 10%).



The compound does not pass the intact blood-brain barrier and diffuses through the placental barrier only to a small extent.



• Metabolism



Gadoxetate disodium is not metabolized.



• Elimination



Gd-EOB-DTPA is equally eliminated via the renal and hepatobiliary routes. The half–life of Gd-EOB-DTPA was approximately 1.0 hour. The pharmacokinetics was dose-linear up to the dose of 0.4 ml/kg (100 micromol/kg).



A total serum clearance (Cltot) of about 250 ml/min was recorded, whereas the renal clearance (Clr) corresponds to about 120 ml/min.



• Characteristics in special patient populations



Elderly population (aged 65 years and above)



In accordance with the physiological changes in renal function with age, the plasma clearance of gadoxetate disodium was reduced from 210 ml/min in non-elderly subjects to 163 ml/min in elderly subjects aged 65 years and above. Terminal half-life and systemic exposure were higher in the elderly (2.3 h and 197 µmol*h/l, compared to 1.6 h and 153 µmol*h/l, respectively). The renal excretion was complete after 24 h in all subjects with no difference between elderly and non-elderly healthy subjects.



Renal and/or hepatic impairment



In patients with mild and moderate hepatic impairment, a slight to moderate increase in plasma concentration, half-life and urinary excretion, as well as decrease in hepatobiliary excretion have been observed in comparison to subjects with normal liver function. However, no clinically relevant differences in hepatic signal enhancement were observed. In patients with severe hepatic impairment, especially in patients with abnormally high ( > 3 mg/dl) serum bilirubin levels, the AUC was increased to 259 µmol*h/l compared to 160 µmol*h/l in the control group. The elimination half-life was increased to 2.6 h compared to 1.8 h in the control group. The hepatobiliary excretion substantially decreased to 5.7% of the administered doseand the hepatic signal enhancement is reduced in these patients.



In patients with end-stage renal failure the AUC increased 6-fold to about 903 µmol*h/l and the terminal half-life was prolonged to about 20 h. Hemodialysis increased the clearance of gadoxetate disodium (see section 4.4). In an average dialysis session of about 3-hour duration, about 30% of the gadoxetate disodium dose was removed by hemodialysis starting 1 hour post injection. In addition to clearance by hemodialysis, a significant fraction of the administered gadoxetate dose is biliary excreted in these patients as shown by a mean recovery of about 50% in faeces within 4 days (range 24.6 to 74.0%, n=6 patients).



5.3 Preclinical Safety Data



Preclinical data reveal no special hazard for humans based on conventional studies of acute and subchronic toxicity, genotoxicity and contact-sensitising potential.



• Cardiac safety



In telemetered conscious dogs a small and transient QT prolongation was observed at the highest dose tested of 0.5 mmol/kg, which represents 20 times the human dose. At high concentrations, Gd-EOB-DTPA blocked the HERG channel and prolonged the action potential duration in isolated guinea pig papillary muscles. This indicates a possibility that Primovist might induce QT prolongation when overdosed.



No findings have been observed in safety pharmacology studies in other organ systems.



• Reproduction toxicology and lactation



In a rabbit embryotoxicity study, an increased number of postimplantational losses and increased abortion rate were observed after repeated administration of 2.0 mmol/kg of Gd-EOB-DTPA, representing 25.9 times (based on body surface area) or approx. 80 times (based on body weight) the recommended human dose.



In lactating rats, less than 0.5% of the intravenously administered dose (0.1 mmol/kg) of radioactively labelled gadoxetate was excreted into the breast milk. Absorption after oral administration was very low in rats with 0.4%.



• Local tolerance



Local intolerance reactions were only observed after intramuscular administration of Gd-EOB-DTPA.



• Carcinogenicity



No carcinogenicity studies were performed.



6. Pharmaceutical Particulars



6.1 List Of Excipients



Caloxetate trisodium



Hydrochloric acid (for pH adjustment)



Sodium hydroxide (for pH adjustment)



Trometamol



Water for injections



6.2 Incompatibilities



In the absence of compatibility studies, this medicinal product must not be mixed with other medicinal products.



6.3 Shelf Life



5 years.



The product should be used immediately after opening.



6.4 Special Precautions For Storage



This medicinal product does not require any special storage precautions.



6.5 Nature And Contents Of Container



10 ml prefilled syringes consisting of a colourless siliconized PhEur type I glass barrel, a siliconized chlorobutyl elastomer plunger stopper, a chlorobutyl elastomer rubber tip cap, a polysulfone Luer Lock adapter and a polypropylene safety cap.



• Package sizes:



1, 5 and 10 x 5 ml (in 10 ml prefilled syringe)



1, 5 and 10 x 7.5 ml (in 10 ml prefilled syringe)



1, 5 and 10 x 10 ml (in 10 ml prefilled syringe)



Not all pack sizes may be marketed.



6.6 Special Precautions For Disposal And Other Handling



• Inspection



This medicinal product is a clear, colourless to pale yellow solution. It should be visually inspected before use.



Primovist should not be used in case of severe discolouration, the occurrence of particulate matter or a defective container.



• Handling



The prefilled syringe must be taken from the pack and prepared for the injection immediately before the examination.



The tip cap should be removed from the prefilled syringe immediately before use



• Disposal



Any unused product should be disposed of in accordance with local requirements.



The peel-off tracking label on the pre-filled syringes should be stuck onto the patient record to enable accurate recording of the gadolinium contrast agent used. The dose used should also be recorded.



7. Marketing Authorisation Holder



Bayer plc



Bayer House



Strawberry Hill



Newbury



Berks RG14 1JA



8. Marketing Authorisation Number(S)



PL 00010/0555



9. Date Of First Authorisation/Renewal Of The Authorisation



27 April 2009



10. Date Of Revision Of The Text



28 September 2011




Friday, 7 September 2012

Iron/Vitamin B Complex/Vitamin C/Folic Acid Caplets


Pronunciation: VYE-ta-min/FOE-lik AS-id/EYE-urn
Generic Name: Vitamin B Complex/Vitamin C/Folic Acid/
Brand Name: Examples include Foli-Iron and I-Fol Plus

Accidental overdose of products that contain iron is a leading cause of fatal poisoning in children younger than 6 years old. Keep this and all medicines out of the reach of children. In case of accidental ingestion, call the poison control center or a doctor at once.





Iron/Vitamin B Complex/Vitamin C/Folic Acid Caplets are used for:

Preventing and treating low iron levels in the body. It may also be used for other conditions as determined by your doctor.


Iron/Vitamin B Complex/Vitamin C/Folic Acid Caplets are an iron, vitamin, and folic acid combination. It works by providing iron, vitamins, and folic acid to the body.


Do NOT use Iron/Vitamin B Complex/Vitamin C/Folic Acid Caplets if:


  • you are allergic to any ingredient in Iron/Vitamin B Complex/Vitamin C/Folic Acid Caplets

  • you have high levels of iron in the blood (eg, hemochromatosis, hemosiderosis)

  • you have pernicious anemia

Contact your doctor or health care provider right away if any of these apply to you.



Before using Iron/Vitamin B Complex/Vitamin C/Folic Acid Caplets:


Some medical conditions may interact with Iron/Vitamin B Complex/Vitamin C/Folic Acid Caplets. Tell your doctor or pharmacist if you have any medical conditions, especially if any of the following apply to you:


  • if you are pregnant, planning to become pregnant, or are breast-feeding

  • if you are taking any prescription or nonprescription medicine, herbal preparation, or dietary supplement

  • if you have allergies to medicines, foods, or other substances

  • if you have any other type of anemia (eg, hemolytic anemia)

  • if you have stomach or bowel problems (eg, Crohn disease, inflammation, ulcer), metabolism problems, the blood disease porphyria, or other blood problems (eg, thalassemia)

  • if you have a bleeding problem, have had multiple blood transfusions, or are receiving dialysis

Some MEDICINES MAY INTERACT with Iron/Vitamin B Complex/Vitamin C/Folic Acid Caplets. Tell your health care provider if you are taking any other medicines, especially any of the following:


  • Fluorouracil because the risk of its side effects may be increased by Iron/Vitamin B Complex/Vitamin C/Folic Acid Caplets

  • Doxycycline, hydantoins (eg, phenytoin), mycophenolate, penicillamine, or thyroid hormones (eg, levothyroxine) because their effectiveness may be decreased by Iron/Vitamin B Complex/Vitamin C/Folic Acid Caplets

This may not be a complete list of all interactions that may occur. Ask your health care provider if Iron/Vitamin B Complex/Vitamin C/Folic Acid Caplets may interact with other medicines that you take. Check with your health care provider before you start, stop, or change the dose of any medicine.


How to use Iron/Vitamin B Complex/Vitamin C/Folic Acid Caplets:


Use Iron/Vitamin B Complex/Vitamin C/Folic Acid Caplets as directed by your doctor. Check the label on the medicine for exact dosing instructions.


  • Take Iron/Vitamin B Complex/Vitamin C/Folic Acid Caplets by mouth with or without food. If stomach upset occurs, take with food to reduce stomach irritation.

  • If you also take bisphosphonates (eg, alendronate), cefdinir, methyldopa, a quinolone antibiotic (eg, ciprofloxacin), or a tetracycline antibiotic (eg, minocycline), ask your doctor or pharmacist how to take it with Iron/Vitamin B Complex/Vitamin C/Folic Acid Caplets.

  • If you miss a dose of Iron/Vitamin B Complex/Vitamin C/Folic Acid Caplets, take it as soon as possible. If it is almost time for your next dose, skip the missed dose and go back to your regular dosing schedule. Do not take 2 doses at once.

Ask your health care provider any questions you may have about how to use Iron/Vitamin B Complex/Vitamin C/Folic Acid Caplets.



Important safety information:


  • Do not take more than the recommended dose without checking with your doctor.

  • Do not take large doses of vitamins (megadoses or megavitamin therapy) while you use Iron/Vitamin B Complex/Vitamin C/Folic Acid Caplets unless your doctor tells you to.

  • Iron/Vitamin B Complex/Vitamin C/Folic Acid Caplets has pyridoxine (vitamin B6), folic acid, and iron in it. Before you start any new medicine, check the label to see if it also has pyridoxine, folic acid, or iron in it too. If it does or if you are not sure, check with your doctor or pharmacist.

  • Iron/Vitamin B Complex/Vitamin C/Folic Acid Caplets may interfere with certain lab tests, such as tests used to check for blood in the stool. Be sure your doctor and lab personnel know you are taking Iron/Vitamin B Complex/Vitamin C/Folic Acid Caplets.

  • Iron/Vitamin B Complex/Vitamin C/Folic Acid Caplets should be used with extreme caution in CHILDREN; safety and effectiveness in children have not been confirmed.

  • PREGNANCY and BREAST-FEEDING: If you become pregnant, contact your doctor. You will need to discuss the benefits and risks of using Iron/Vitamin B Complex/Vitamin C/Folic Acid Caplets while you are pregnant. Iron/Vitamin B Complex/Vitamin C/Folic Acid Caplets are found in breast milk. If you are or will be breast-feeding while you use Iron/Vitamin B Complex/Vitamin C/Folic Acid Caplets, check with your doctor. Discuss any possible risks to your baby.


Possible side effects of Iron/Vitamin B Complex/Vitamin C/Folic Acid Caplets:


All medicines may cause side effects, but many people have no, or minor side effects. Check with your doctor if any of these most COMMON side effects persist or become bothersome:



Constipation; dark or green stools; diarrhea; nausea; stomach pain; vomiting.



Seek medical attention right away if any of these SEVERE side effects occur:

Severe allergic reactions (rash; hives; itching; difficulty breathing; tightness in the chest; swelling of the mouth, face, lips, or tongue); black, tarry, or bloody stools; severe or persistent stomach pain.



This is not a complete list of all side effects that may occur. If you have questions or need medical advice about side effects, contact your doctor or health care provider. You may report side effects to FDA at 1-800-FDA-1088 (1-800-332-1088) or at http://www.fda.gov/medwatch.



If OVERDOSE is suspected:


Contact 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center, or emergency room immediately. Symptoms may include black, tarry, or bloody stools; blue or unusually pale skin; drowsiness or dizziness; fast heartbeat; increased thirst or urination; seizures; severe or persistent nausea, vomiting, diarrhea, or stomach pain; sluggishness; vomiting blood; weakness.


Proper storage of Iron/Vitamin B Complex/Vitamin C/Folic Acid Caplets:

Store Iron/Vitamin B Complex/Vitamin C/Folic Acid Caplets at 77 degrees F (25 degrees C). Brief storage at temperatures between 59 and 86 degrees F (15 and 30 degrees C) is permitted. Store away from heat, moisture, and light. Do not store in the bathroom. Keep Iron/Vitamin B Complex/Vitamin C/Folic Acid Caplets out of the reach of children and away from pets.


General information:


  • If you have any questions about Iron/Vitamin B Complex/Vitamin C/Folic Acid Caplets, please talk with your doctor, pharmacist, or other health care provider.

  • Iron/Vitamin B Complex/Vitamin C/Folic Acid Caplets are to be used only by the patient for whom it is prescribed. Do not share it with other people.

  • If your symptoms do not improve or if they become worse, check with your doctor.

  • Check with your pharmacist about how to dispose of unused medicine.

This information is a summary only. It does not contain all information about Iron/Vitamin B Complex/Vitamin C/Folic Acid Caplets. If you have questions about the medicine you are taking or would like more information, check with your doctor, pharmacist, or other health care provider.



Issue Date: February 1, 2012

Database Edition 12.1.1.002

Copyright © 2012 Wolters Kluwer Health, Inc.

More Iron/Vitamin B Complex/Vitamin C/Folic Acid resources


  • Iron/Vitamin B Complex/Vitamin C/Folic Acid Use in Pregnancy & Breastfeeding
  • Iron/Vitamin B Complex/Vitamin C/Folic Acid Drug Interactions
  • Iron/Vitamin B Complex/Vitamin C/Folic Acid Support Group
  • 4 Reviews for Iron/Vitamin B Complex/Vitamin C/Folic Acid - Add your own review/rating


Compare Iron/Vitamin B Complex/Vitamin C/Folic Acid with other medications


  • Vitamin/Mineral Supplementation and Deficiency

Monday, 3 September 2012

Cysview





Dosage Form: intravesical solution
FULL PRESCRIBING INFORMATION

Indications and Usage for Cysview


Cysview is an optical imaging agent indicated for use in the cystoscopic detection of non-muscle invasive papillary cancer of the bladder among patients suspected or known to have lesion(s) on the basis of a prior cystoscopy. Cysview is used with the Karl Storz D-Light C Photodynamic Diagnostic (PDD) system to perform cystoscopy with the blue light setting (Mode 2) as an adjunct to the white light setting (Mode 1).



Limitations of Use


Cysview is not:


  • a replacement for random bladder biopsies or other procedures used in the detection of bladder cancer [see Warnings and Precautions (5.2)].

  • for repetitive use. The potential risks associated with repetitive exposure, including sensitization and adverse effects of blue light have not been evaluated [see Warnings and Precautions (5.1)].


Cysview Dosage and Administration



Recommended Dose


The recommended dose for adults is 50 mL of reconstituted solution of Cysview [see Dosage and Administration (2.2)], instilled into the bladder via a urinary catheter [see Dosage and Administration (2.3)].



Reconstitution of Cysview


Cysview is supplied as a kit containing two vials: a clear glass vial labeled as Cysview (hexaminolevulinate hydrochloride) for Intravesical Solution, containing 100 mg hexaminolevulinate hydrochloride as a powder, and a vial labeled as DILUENT for Cysview, containing 50 mL of the diluent in a polypropylene vial.


Perform all steps under aseptic conditions. Use gloves during the reconstitution procedure; skin exposure to hexaminolevulinate hydrochloride may increase the risk for sensitization to the drug.


Use a 50 mL syringe with a Luer Lock tip throughout the reconstitution procedure to ensure that the correct concentration (2 mg/mL) of the drug is obtained and that a stable syringe-catheter connection is made for the bladder instillation of Cysview.



          Figure 1.


  1. Remove the cap from the sterile 50 mL syringe and carefully retain it for subsequent reattachment to the syringe (step 4). Attach a needle to the syringe and withdraw 50 mL of the diluent (Figure 1).

    Figure 2.

  2. Penetrate the stopper of the Cysview powder vial with the needle and inject 10 mL of the diluent from the syringe into the powder vial (Figure 2).

    Figure 3.

  3. Without withdrawing the needle from the vial, hold the powder vial and syringe in a firm grip (Figure 3) and gently shake to dissolve of the powder in the diluent. The powder normally dissolves almost immediately.

    Figure 4.

  4. Withdraw all of the dissolved solution from the powder vial (10 mL) into the 50 mL syringe (Figure 4).

    Figure 5.

  5. Remove the needle from the powder vial, disconnect the needle from the syringe tip and discard it. Plug the syringe with the syringe cap (Figure 5). Gently mix the contents of the syringe. The reconstituted solution of Cysview is colorless to pale yellow and clear to slightly opalescent, and free from visible particles.

    Figure 6.

  6. Peel off the detachable portion of the label (starting at the corner marked with a black triangle) from the Cysview powder vial and affix it to the syringe containing the solution of Cysview (Figure 6). Add two hours to the present time and write the resulting expiration time and date on the syringe label.

Cysview is now reconstituted and ready for use. Instill the reconstituted solution of Cysview into the bladder. If unable to administer the solution shortly after reconstitution, the solution may be stored for up to 2 hours in a refrigerator at 2°-8°C (36°- 46°F) in the labeled syringe. If not used within 2 hours, discard the solution. [see Dosage and Administration (2.2) and How Supplied/Storage and Handling (16)]



Bladder Instillation of Cysview


For bladder instillation of the solution of Cysview, use straight, or intermittent, urethral catheters with a proximal funnel opening that will accommodate the Luer Lock adapter. Use only catheters made of vinyl (uncoated or coated with hydrogel), latex (amber or red), and silicone to instill the reconstituted Cysview. Do not use catheters coated or embedded with silver or antibiotics. In-dwelling bladder catheters (Foley catheters) may be used if the catheters are inserted shortly prior to Cysview administration and are removed following the Cysview instillation.


Use the following steps for bladder instillation of Cysview:


  1. Using standard sterile catheterization technique, first insert the urethral catheter into the bladder of the patient and use the catheter to completely empty the patient's bladder before instillation of Cysview.

    Figure 7.

  2. To attach the syringe containing the solution of Cysview to the catheter, do the following:
    • Remove the syringe cap from the 50 mL syringe that contains the solution of Cysview.

    • Attach the Luer Lock end of the (provided) catheter adapter to the syringe.

    • Insert the tapered end of the catheter adapter into the funnel opening of the catheter. See Figure 7, with the connection enlarged in the inset.


  3. Slowly instill the solution of Cysview into the bladder through the catheter (Figure 7), ensuring that the complete volume of the syringe (50 mL) is administered.

  4. After the solution is instilled, remove the catheter and instruct the patient to retain the solution within the bladder for at least 1 hour; do not exceed 3 hours [see Dosage and Administration (2.4)]. Patients may stand, sit and move about during the time period between instillation and start of the cystoscopic procedure.

  5. Evacuate the solution of Cysview from the bladder as part of routine emptying of the bladder immediately prior to the initiation of the cystoscopic procedure (refer to the Karl Storz PDD Telescope Instruction manual). Also, the patient may void and completely empty the bladder prior to the procedure.

Avoid skin contact with Cysview. If skin does come in contact with Cysview, wash immediately with soap and water and dry off. After voiding the bladder of Cysview, routinely wash the patient's perineal skin region with soap and water and dry.



Use of the Karl Storz D-Light C Photodynamic Diagnostic (PDD) System


Cysview imaging requires the use of the Karl Storz D-Light C PDD system, which consists of a light source, a camera and a telescope. The light source enables both white light cystoscopy and blue light (wavelength 360 – 450 nm) fluorescence cystoscopy. Familiarity with this system is essential before beginning the procedure and before instilling Cysview into the bladder. For system set up and general information for the safe use of the PDD system, refer to the Karl Storz instruction manual for the PDD system and the instruction manuals for each of the system components. The PDD System is not for use by healthcare providers with green-red color blindness.



Cystoscopic Examination



Training


Training and proficiency in cystoscopic procedures are essential prior to the use of Cysview. Carefully review the instruction manuals provided with the Karl Storz D-Light C Photodynamic Diagnosis (PDD) System. For additional training in the use of the PDD System, contact the manufacturer's representative.



Preparation for Cystoscopy


Initiate the cystoscopic examination within 30 minutes after evacuation of Cysview from the bladder, but no less than 1 or more than 3 hours after Cysview is instilled in the bladder. If the patient did not retain Cysview in the bladder for 1 hour, allow 1 hour to pass from the instillation of Cysview into the bladder to the start of the cystoscopic examination. The efficacy of Cysview has not been established when the solution was retained for less than 1 hour.



Cystoscopic Examination


Empty the patient's bladder and then fill the bladder with a clear fluid (standard bladder irrigation fluid) in order to distend the bladder wall for cystoscopic visibility. Ensure adequate irrigation during examination of the bladder; blood, urine or floating particles in the bladder may interfere with visualization under both white light and blue light.


First perform a complete cystoscopic examination of the entire bladder under white light (Mode 1) and then repeat the examination of the entire bladder surface under blue light (Mode 2) unless the white light cystoscopy reveals extensive mucosal inflammation. Do not perform the blue light cystoscopy if the white light cystoscopy reveals wide-spread mucosal inflammation. Abnormalities of the bladder mucosa during blue light cystoscopy are characterized by the detection of red, homogenous and intense fluorescence. The margins of the abnormal lesions are typically well-demarcated and in contrast to the normal urothelium, which appears blue. Register and document (map) the location and appearance (e.g. papillary) of suspicious lesions and abnormalities seen under either white or blue light.


During the cystoscopic examination, be aware that:


  • a red fluorescence is expected at the bladder outlet and the prostatic urethra; this fluorescence occurs in normal tissue and is usually less intense and more diffuse than the bladder mucosal fluorescence associated with malignant lesions.

  • tangential light may give false fluorescence. To help avoid false fluorescence, hold the endoscope perpendicular and close to the bladder wall with the bladder distended.

  • false positive fluorescence may result from scope trauma from a previous cystoscopic examination and/or bladder inflammation [see Warnings and Precautions (5.3)].

  • malignant lesions may not fluoresce following Cysview administration, particularly if the lesions are coated with necrotic tissue. Blue light may fail to detect T2 tumors which have a tendency to be necrotic on the surface, and necrotic cells generally do not fluoresce [see Warnings and Precautions (5.3)].

  • when performing the blue light cystocopy, avoid prolonged blue light exposure. Studies have not evaluated the potential for adverse effects from blue light. In the controlled clinical trial, the cumulative blue light exposure from bladder mapping did not exceed 12 minutes and checking for complete tumor resection under blue light did not exceed 8 minutes for any patient [see Clinical Studies (14)].

Perform biopsy and/or resection of suspicious lesions by transurethral resection of the bladder (TURB) only after completing white and blue light cystoscopic examinations with bladder mapping. Using standard cystoscopic practices, obtain biopsies of abnormal areas identified during either white or blue light examination and perform resections. Always check for the completeness of the resections under both white light and blue light before finalizing the TURB procedure.



Dosage Forms and Strengths


Cysview (hexaminolevulinate hydrochloride) is supplied as a kit containing:


  • Cysview (hexaminolevulinate hydrochloride) for Intravesical Solution, 100 mg, as a powder in a 10 mL clear glass vial.

  • DILUENT for Cysview, 50 mL, in a polypropylene vial.

  • One Luer Lock catheter adapter (to connect the syringe containing the reconstituted solution of Cysview to the urethral catheter for bladder instillation of Cysview).

Once reconstituted, the solution of Cysview contains 2 mg/mL of hexaminolevulinate hydrochloride.



Contraindications


Cysview is contraindicated in patients with:


  • porphyria

  • gross hematuria

  • BCG immunotherapy or intravesical chemotherapy within the past 90 days

  • known hypersensitivity to hexaminolevulinate or any derivative of aminolevulinic acid


Warnings and Precautions



Anaphylaxis


Anaphylaxis, including anaphylactoid shock, has been reported following administration of Cysview [see Adverse Reactions (6.2)]. Prior to and during use of the Cysview, have trained personnel and therapies available for the treatment of anaphylaxis. The safety of repetitive Cysview exposures has not been evaluated.



Failed Detection


Cysview may fail to detect some bladder tumors, including malignant lesions. Cysview is not a replacement for random biopsies or any other procedure usually performed in the cystoscopic evaluation for cancer. In the controlled clinical trial, Cysview failed to detect 10% of lesions confirmed as malignant within the study drug group [see Clinical Studies (14)]. Do not perform cystoscopy with blue light alone as malignant lesions can be missed unless the bladder is initially examined under white light [see Dosage and Administration (2.5)].



False Fluorescence


Fluorescent areas detected during blue light cystoscopy may not indicate a bladder mucosal lesion. In the controlled clinical study, biopsies from one of every four fluorescent areas showed neither dysplasia nor carcinoma, if the areas were not also identified during white light cystoscopy [see Clinical Studies (14)]. In addition to these false detections, fluorescent areas within the bladder mucosa may result from inflammation, cystoscopic trauma, scar tissue or bladder mucosal biopsy from a previous cystoscopic examination.


The presence of urine and/or blood within the bladder may interfere with the detection of tissue fluorescence. To enhance the diagnostic utility of Cysview with the Karl Storz D-Light C PDD System:


  • ensure the bladder is emptied of urine prior to the instillation of fluids at cystoscopy;

  • biopsy/resect bladder mucosal lesions only following completion of both white light and blue light cystoscopy;


Adverse Reactions


Anaphylaxis has been reported following exposure to Cysview [see Warnings and Precautions (5.1)].



Clinical Study Experience


Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.


In six clinical trials, safety data were obtained from 1,324 patients, aged 32 to 96 years with a median age of 69 years, all primarily Caucasian and approximately 75% male. All patients were evaluated after a single instillation of 50 mL solution of Cysview. Of these patients, 161 (12.2%) patients reported at least one adverse reaction. The most common adverse reaction was bladder spasm (reported in 2.2% of the patients) followed by dysuria, hematuria, and bladder pain. No patients experienced anaphylaxis. In the controlled clinical study, adverse reactions were similar in nature and rate between the study drug group and the control group [see Clinical Studies (14)].



Postmarketing Experience


Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.


Anaphylactoid shock, hypersensitivity reactions, bladder pain, cystitis and abnormal urinalysis have been reported during post marketing use of Cysview.



Drug Interactions


No specific drug interaction studies have been performed.



USE IN SPECIFIC POPULATIONS



Pregnancy



Pregnancy Category C: There are no adequate and well-controlled studies in pregnant women. Adequate reproductive and developmental toxicity studies in animals have not been performed. Cysview should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.



Nursing Mothers


It is not known whether hexaminolevulinate is excreted in human milk. Because many drugs are excreted in human milk, exercise caution when Cysview is administered to nursing mothers.



Pediatric Use


Safety and effectiveness in pediatric patients have not been established.



Geriatric Use


Of 1823 subjects in clinical studies of Cysview, 67% were 65 years and over while 34% were 75 years and over. No clinically important differences in safety or efficacy have been observed between older and younger patients in the controlled study.



Overdosage


No adverse events were reported in a dose-finding study conducted among patients whose bladders were instilled with twice the recommended concentration (dose) of solution of Cysview.



Cysview Description


Cysview contains hexaminolevulinate hydrochloride, an optical imaging drug that in solution form is instilled intravesically for use with photodynamic blue light cystoscopy as an adjunct to white light cystoscopy.


The chemical formula for hexaminolevulinate hydrochloride is C11H21NO3•HCl. Its molecular weight is 251.76 and it has the following structural formula:



Cysview (hexaminolevulinate hydrochloride) for Intravesical Solution is intended for intravesical administration only after reconstitution with the supplied 50 mL DILUENT. Cysview (hexaminolevulinate hydrochloride) for Intravesical Solution and DILUENT for Cysview are supplied together as a kit.


Cysview (hexaminolevulinate hydrochloride) for Intravesical Solution is supplied as a sterile, non-pyrogenic, freeze-dried, white to off-white or pale yellow, powder containing 100 mg of hexaminolevulinate hydrochloride (equivalent of 85 mg of hexaminolevulinate) in a 10 mL clear glass vials. The DILUENT for Cysview is a sterile, non-pyrogenic solution (pH 6) containing 0.61 mg/mL disodium hydrogen phosphate, 0.58 mg/mL of potassium dihydrogen phosphate, 7.02 mg/mL of sodium chloride, hydrochloric acid, sodium hydroxide, and water for injection. It is a clear, colorless solution, free from visible particles, and is provided in a 50 mL polypropylene vial.


The reconstituted solution of Cysview contains 2 mg/mL of hexaminolevulinate hydrochloride and is colorless to pale yellow. It is free from visible particles and has a pH between 5.7 and 6.2.



Cysview - Clinical Pharmacology



Mechanism of Action


Cysview is an ester of the heme precursor, aminolevulinic acid. After bladder instillation, Cysview enters the bladder mucosa and is proposed to enter the intracellular space of mucosal cells where it is used as a precursor in the formation of the photoactive intermediate protoporphyrin IX (PpIX) and other photoactive porphyrins (PAPs). PpIX and PAPs are reported to accumulate preferentially in neoplastic cells as compared to normal urothelium, partly due to altered enzymatic activity in the neoplastic cells. After excitation with light at wavelengths between 360 and 450 nm, PpIX and other PAPs return to a lower energy level by fluorescing, which can be detected and used for cystoscopic detection of lesions. The fluorescence from tumor tissue appears bright red and demarcated, whereas the background normal tissue appears dark blue. Similar processes may occur in inflamed cells.



Pharmacodynamics


In vitro studies have shown increased porphyrin fluorescence in normal urothelium after exposure to Cysview. In the human bladder, a greater accumulation of porphyrins is proposed in neoplastic or inflamed cells, compared to normal urothelium. After bladder instillation of Cysview for approximately 1 hour and subsequent illumination with blue light at wavelengths 360 – 450 nm, the porphyrins will fluoresce red [see Dosage and Administration (2.5)].



Pharmacokinetics


After bladder instillation of [14C]-labeled Cysview (100 mg) for approximately 1 hour in healthy volunteers, absolute bioavailability of Cysview was 7% (90% confidence interval [CI]: 5%-10%). The [14C]-labeled substance(s) showed biphasic elimination, with an initial elimination half-life of 39 minutes, followed by a terminal half-life of approximately 76 hours. Whole blood analysis showed no evidence of significant binding of Cysview to erythrocytes. An in vitro study showed that Cysview underwent rapid metabolism in human blood.



Nonclinical Toxicology



Carcinogenesis, Mutagenesis, Impairment of Fertility


No studies in animals have been conducted to evaluate the carcinogenic potential of hexaminolevulinate hydrochloride.


Hexaminolevulinate hydrochloride was not mutagenic in in vitro reverse mutation tests in bacteria, or in chromosome aberration tests in human peripheral blood lymphocytes, and was negative in an in vivo micronucleus test in mice after intravenous injection of doses up to 45 mg/kg in the absence of light activation. Adequate studies have not been performed to evaluate the genetic toxicity of hexaminolevulinate hydrochloride in the presence of light activation.


Adequate reproductive and developmental toxicity studies in animals have not been performed to evaluate the effects of hexaminolevulinate hydrochloride on fertility.



Animal Toxicology and/or Pharmacology


Dose dependent neurological effects such as tremor, increased motor activity, and increased startle and touch escape responses were observed immediately after dosing at doses ≥ 30 mg/kg (24 times human systemic exposure based on the body surface area, using 10% as the upper level of 90% confidence interval of bioavailability) in a single dose rat study. The animals recovered to normal status by 60 min after dosing. Adverse neurological effects were also noted in other single or repeat dose toxicity studies.


Hexaminolevulinate hydrochloride had moderate to strong potential to cause skin sensitization based on a local lymph node assay in mouse.



Clinical Studies


The safety and efficacy of Cysview when used with photodynamic cystoscopy were studied in a prospective, multicenter, controlled clinical trial. Adult patients with known or suspected bladder cancer were randomized to either white light (WL) cystoscopy (control group, n = 384) or WL followed by blue light (BL) cystoscopy (study drug group, n = 395). Only the study drug group patients received Cysview by bladder instillation prior to cystoscopy. After bladder evacuation of Cysview, bladder lesion mapping was performed initially using the Karl Storz PDD system in the WL mode followed by lesion mapping in the BL mode. Control group patients underwent only WL cystoscopy with lesion mapping. The average age of the randomized patients was 69 years (range 24 to 96); 78% were male and 94% were Caucasian. All patients had previously undergone cystoscopy.


The main diagnostic efficacy outcome was assessed within the study drug group. This assessment compared lesions detected during an initial cystoscopic examination to their centralized histologic findings (the standard of truth). Following the initial diagnostic cystoscopy, patients within both study groups who had histologically confirmed Ta and/or T1 lesions underwent follow-up WL cystoscopy at 3, 6 and 9 months; these histologic evaluations were based upon the site assessments at both the initial and follow-up cystoscopy.


Diagnostic efficacy assessed the number of patients within the study drug group who had at least one additional Ta or T1 bladder cancer detected only by BL; the proportion of these patients was compared to a proposed threshold proportion of 10%. Within the study drug group, 286 patients had at least one Ta and/or T1 lesion, including 47 patients who had at least one of the lesions detected only by BL (see Table 1).











Table 1: BL Cystoscopic Ta and/or T1 Lesion Detection within the Study Drug Group

*

exact test comparison of the proportion to a threshold value of 10%

Number of patients with any Ta and/or T1 lesion detected with either WL or BL286
Number (%) of patients with any Ta and/or T1 lesion detected only with BL47 (16%)
p-value*0.001

Some malignant lesions were detected only by WL or BL (see Table 2).
























Table 2: Bladder Tumor Detection within the Study Drug Group by WL and/or BL Cystoscopy
Number of lesionsDetected by Both WL & BLDetected by WL OnlyDetected by BL Only
CIS, n = 6633627
Ta, n = 5804725256
T1, n = 9576109
T2 – T4, n = 473881

Among the lesions detected only by BL, 23% were negative for any carcinoma-related pathology, including dysplasia. Among the lesions detected only by WL, 17% were negative for any carcinoma-related pathology, including dysplasia.



How Supplied/Storage and Handling


Cysview is supplied as a kit labeled Cysview (hexaminolevulinate hydrochloride) Kit for Intravesical Solution, 100 mg. The kit contains:


  • One vial of Cysview (hexaminolevulinate hydrochloride) for Intravesical Solution, 100 mg, as a powder in a 10 mL clear glass vial.

  • One vial of DILUENT for Cysview, 50 mL, in a polypropylene vial.

  • One Luer Lock catheter adapter (to connect the syringe containing Cysview solution to the urethral catheter during instillation of Cysview).

NDC 10511-3001-1



Storage


Store Cysview (hexaminolevulinate hydrochloride) Kit for Intravesical Solution at 20°-25°C (68°-77°F); excursions are permitted to 15°-30°C (59°-86°F). Do not use beyond the expiry date printed on the carton.


Use the solution of Cysview shortly after reconstitution. If unable to use within this time period, the reconstituted solution can be stored under refrigeration at 2°-8°C (36°-46°F) for up to 2 hours in the 50 mL labeled syringe.



Patient Counseling Information


Ask patients if they have:


  • a diagnosis or a family history of porphyria

  • allergy to aminolevulinic acid or prior exposure to Cysview

  • gross hematuria

  • had BCG immunotherapy or chemotherapy within the bladder.

Inform patients that Cysview should be retained in the bladder for 1 hour from instillation of Cysview to the start of the cystoscopic procedure. If the patient cannot hold Cysview for 1 hour, but needs to void and expel Cysview from the bladder, he or she may void and should then inform a health care professional [see Dosage and Administration (2)].



Distributed by

Photocure Inc.

Princeton, NJ 08540 U.S.A.


Packaged and Labeled by

Orifice Medical AB

Ystad, Sweden


Cysview is a trademark of Photocure ASA.


Photodynamic Diagnostic (PDD) system is a

trademark of Karl Storz Endoscopy-America, Inc.


Photocure and the Photocure logo are trademarks of Photocure ASA.

© 2011 Photocure ASA – All rights reserved.


PL01-05-01



PRINCIPAL DISPLAY PANEL - 100 mg Kit Carton


PHOTOCURE®


Rx ONLY


Sterile.

Single Use Containers.

Discard unused portion.


ONE KIT


NDC 10511-3001-1


Cysview®

(hexaminolevulinate HCl)

KIT for Intravesical Solution


100 mg


For Bladder Instillation Only after

Reconstitution


Each KIT contains:


 

1 vial Cysview®(hexaminolevulinate HCl) for

Intravesical Solution 100 mg

 

1 vial DILUENT for Cysview®

 

1 Luer Lock catheter adapter

Reconstitution with supplied DILUENT for Cysview®

required before use (see insert).
























Cysview 
hexaminolevulinate hydrochloride  kit






Product Information
Product TypeHUMAN PRESCRIPTION DRUGNDC Product Code (Source)10511-3001










Packaging
#NDCPackage DescriptionMultilevel Packaging
110511-3001-11 KIT In 1 VIAL, PATENT DELIVERY SYSTEMNone











QUANTITY OF PARTS
Part #Package QuantityTotal Product Quantity
Part 11 VIAL, GLASS  50 mL
Part 21 VIAL  50 mL



Part 1 of 2
Cysview 
hexaminolevulinate hydrochloride  injection, powder, lyophilized, for solution










Product Information
   
Route of AdministrationINTRAVESICALDEA Schedule    








Active Ingredient/Active Moiety
Ingredient NameBasis of StrengthStrength
hexaminolevulinate hydrochloride (hexaminolevulinate)hexaminolevulinate hydrochloride100 mg  in 50 mL





Inactive Ingredients
Ingredient NameStrength
No Inactive Ingredients Found


















Product Characteristics
Color    Score    
ShapeSize
FlavorImprint Code
Contains      










Packaging
#NDCPackage DescriptionMultilevel Packaging
150 mL In 1 VIAL, GLASSNone










Marketing Information
Marketing CategoryApplication Number or Monograph CitationMarketing Start DateMarketing End Date
NDANDA02255509/01/2010




Part 2 of 2
DILUENT FOR Cysview 
diluent  injection










Product Information
   
Route of AdministrationINTRAVESICALDEA Schedule    






Active Ingredient/Active Moiety
Ingredient NameBasis of StrengthStrength
No Active Ingredients Found














Inactive Ingredients
Ingredient NameStrength
potassium phosphate, monobasic 
sodium chloride 
hydrochloric acid 
sodium hydroxide 
water 


















Product Characteristics
Color    Score    
ShapeSize
FlavorImprint Code
Contains      










Packaging
#NDCPackage DescriptionMultilevel Packaging
150 mL In 1 VIALNone










Marketing Information
Marketing CategoryApplication Number or Monograph CitationMarketing Start DateMarketing End Date
NDANDA02255509/01/2011











Marketing Information
Marketing CategoryApplication Number or Monograph CitationMarketing Start DateMarketing End Date
NDANDA02255509/01/2011


Labeler - Photocure Inc. (006629060)









Establishment
NameAddressID/FEIOperations
Ben Venue Laboratories, Inc.004327953MANUFACTURE









Establishment
NameAddressID/FEIOperations
Fresenius Kabi Norge AS731170932MANUFACTURE









Establishment
NameAddressID/FEIOperations
Orifice Medical AB508917689LABEL, PACK
Revised: 12/2011Photocure Inc.

Saturday, 1 September 2012

Tetrahydrozoline Drops


Pronunciation: te-tra-hye-DROZ-oh-leen
Generic Name: Tetrahydrozoline
Brand Name: Examples include Eye Moisturizing Relief and Murine Tears


Tetrahydrozoline Drops are used for:

Temporarily relieving redness, burning, and irritation caused by dry eyes. It may also be used for other conditions as determined by your doctor.


Tetrahydrozoline Drops are an eye decongestant and lubricant. It works by constricting the blood vessels in the eye and coating the eye, which relieves redness and dryness.


Do NOT use Tetrahydrozoline Drops if:


  • you are allergic to any ingredient in Tetrahydrozoline Drops

  • you have taken furazolidone or a monoamine oxidase (MAO) inhibitor (eg, phenelzine) within the past 14 days

Contact your doctor or health care provider right away if any of these apply to you.



Before using Tetrahydrozoline Drops:


Some medical conditions may interact with Tetrahydrozoline Drops. Tell your doctor or pharmacist if you have any medical conditions, especially if any of the following apply to you:


  • if you are pregnant, planning to become pregnant, or are breast-feeding

  • if you are taking any prescription or nonprescription medicine, herbal preparation, or dietary supplement

  • if you have allergies to medicines, foods, or other substances

  • if you have glaucoma, high blood pressure, diabetes, heart problems, or thyroid problems, or you are taking medicine for high blood pressure

Some MEDICINES MAY INTERACT with Tetrahydrozoline Drops. Tell your health care provider if you are taking any other medicines, especially any of the following:


  • Tricyclic antidepressants (eg, amitriptyline) because they may decrease Tetrahydrozoline Drops's effectiveness

  • Cocaine, furazolidone, MAO inhibitors (eg, phenelzine), or tricyclic antidepressants (eg, amitriptyline) because they may increase the risk of Tetrahydrozoline Drops's side effects, such as headache, fever, and high blood pressure

  • Bromocriptine or cocaine because their actions and side effects may be increased by Tetrahydrozoline Drops

This may not be a complete list of all interactions that may occur. Ask your health care provider if Tetrahydrozoline Drops may interact with other medicines that you take. Check with your health care provider before you start, stop, or change the dose of any medicine.


How to use Tetrahydrozoline Drops:


Use Tetrahydrozoline Drops as directed by your doctor. Check the label on the medicine for exact dosing instructions.


  • Tetrahydrozoline Drops are for use in the eye only. Avoid contact with the nose, mouth, or other mucous membranes.

  • To use Tetrahydrozoline Drops, first, wash your hands. Tilt your head back. Using your index finger, pull the lower eyelid away from the eye to form a pouch. Drop the medicine into the pouch and gently close your eyes. Immediately use your finger to apply pressure to the inside corner of the eye for 1 to 2 minutes. Do not blink. Remove excess medicine around your eye with a clean tissue, being careful not to touch your eye. Wash your hands to remove any medicine that may be on them.

  • To prevent germs from contaminating your medicine, do not touch the applicator tip to any surface, including your eye. Keep the container tightly closed.

  • If you miss a dose of Tetrahydrozoline Drops and you are using it regularly, use it as soon as possible. If it is almost time for your next dose, skip the missed dose and go back to your regular dosing schedule.

Ask your health care provider any questions you may have about how to use Tetrahydrozoline Drops.



Important safety information:


  • Remove contact lenses before using Tetrahydrozoline Drops.

  • Do not use Tetrahydrozoline Drops if it becomes cloudy or changes color.

  • Contact your doctor if you experience changes in your vision, eye pain, irritation, soreness, or continued redness, or if your condition does not improve after 3 days.

  • Use Tetrahydrozoline Drops with caution in CHILDREN because they may be more sensitive to its effects.

  • PREGNANCY and BREAST-FEEDING: If you become pregnant while taking Tetrahydrozoline Drops, discuss with your doctor the benefits and risks of using Tetrahydrozoline Drops during pregnancy. It is unknown if Tetrahydrozoline Drops are excreted in breast milk. If you are or will be breast-feeding while you are using Tetrahydrozoline Drops, check with your doctor or pharmacist to discuss the risks to your baby.


Possible side effects of Tetrahydrozoline Drops:


All medicines may cause side effects, but many people have no, or minor, side effects. Check with your doctor if any of these most COMMON side effects persist or become bothersome:



Blurred vision; minor stinging when the medicine is dropped into the eye.



Seek medical attention right away if any of these SEVERE side effects occur:

Severe allergic reactions (rash; hives; difficulty breathing; tightness in the chest; swelling of the mouth, face, lips, or tongue); changes in vision; eye pain; worsening or persistent eye irritation or redness.



This is not a complete list of all side effects that may occur. If you have questions about side effects, contact your health care provider. Call your doctor for medical advice about side effects. To report side effects to the appropriate agency, please read the Guide to Reporting Problems to FDA.



If OVERDOSE is suspected:


Contact 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center, or emergency room immediately. Tetrahydrozoline Drops may be harmful if swallowed, especially in children.


Proper storage of Tetrahydrozoline Drops:

Store Tetrahydrozoline Drops at room temperature, between 59 and 86 degrees F (15 and 30 degrees C). Store away from heat, moisture, and light. Do not store in the bathroom. Keep Tetrahydrozoline Drops out of the reach of children and away from pets.


General information:


  • If you have any questions about Tetrahydrozoline Drops, please talk with your doctor, pharmacist, or other health care provider.

  • Tetrahydrozoline Drops are to be used only by the patient for whom it is prescribed. Do not share it with other people.

  • If your symptoms do not improve or if they become worse, check with your doctor.

  • Check with your pharmacist about how to dispose of unused medicine.

This information is a summary only. It does not contain all information about Tetrahydrozoline Drops. If you have questions about the medicine you are taking or would like more information, check with your doctor, pharmacist, or other health care provider.



Issue Date: February 1, 2012

Database Edition 12.1.1.002

Copyright © 2012 Wolters Kluwer Health, Inc.

More Tetrahydrozoline resources


  • Tetrahydrozoline Use in Pregnancy & Breastfeeding
  • Tetrahydrozoline Drug Interactions
  • Tetrahydrozoline Support Group
  • 1 Review for Tetrahydrozoline - Add your own review/rating


Compare Tetrahydrozoline with other medications


  • Eye Dryness/Redness